LVTX

Tender Offer Success: LAVA Therapeutics announced that approximately 87% of its outstanding common shares were validly tendered in the offer from XOMA Royalty, satisfying the minimum tender condition for the acquisition.

Subsequent Offering Period: A subsequent offering period has begun for LAVA shareholders who have not yet tendered their shares, which will end on November 20, 2025, with shares expected to be suspended from trading on Nasdaq shortly thereafter.

Voluntary Delisting: LAVA has notified Nasdaq of its intention to voluntarily delist its common shares, contingent upon the completion of the acquisition by XOMA Royalty.

Forward-Looking Statements: The press release includes cautionary notes regarding forward-looking statements, highlighting various risks and uncertainties that could affect the completion of the tender offer and LAVA's business operations.

Investigation Announcement: The Ademi Firm is investigating Lava (Nasdaq: LVTX) for potential breaches of fiduciary duty related to its transaction with XOMA Royalty, including concerns over the terms of the deal and the conduct of Lava's board of directors.

Transaction Details: Under the amended agreement, Lava shareholders will receive a reduced initial cash amount of $1.04 per share and a contingent value right, while the minimum net-cash closing condition has been lowered from $31.5 million to $24.5 million, raising concerns about the limitations on competing bids.